Spero Therapeutics, Inc. License Agreements
11 Contracts & Agreements
- Amendment 4 to Exclusive License Agreement, dated October 28, 2024, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on November 14, 2024)
- Amendment 2 to Exclusive License Agreement, dated December 20, 2023, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on March 13, 2024)
- Amendment 1 to Exclusive License Agreement, dated July 4, 2023, by and between the Registrant and GlaxoSmithKline Intellectual Property (No. 3) Limited (Filed With SEC on March 13, 2024)
- License Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc (Filed With SEC on August 5, 2021)
- Amended and Restated License Agreement, dated January 15, 2021, by and between the Registrant and Everest Medicines II Limited (Filed With SEC on March 11, 2021)
- License Agreement, dated January 4, 2019, by and between New Pharma License Holdings Limited and Everest Medicines II Limited (Filed With SEC on March 14, 2019)
- Amended and Restated License Agreement, dated June 28, 2017, by and between Spero Potentiator, Inc. and Northern Antibiotics Oy (Ltd.) (Filed With SEC on October 23, 2017)
- Assignment and License Agreement, dated May 9, 2016, by and among Spero Trinem, Inc., the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on October 23, 2017)
- Amended and Restated License Agreement, dated June 28, 2017, by and between Spero Potentiator, Inc. and Northern Antibiotics Oy (Ltd.) (Filed With SEC on October 6, 2017)
- License Agreement, dated June 14, 2017, by and between the Registrant and Meiji Seika Pharma Co., Ltd., as supplemented by Addendum to License Agreement, dated June 14, 2017 (Filed With SEC on October 6, 2017)
- Assignment and License Agreement, dated May 9, 2016, by and among Spero Trinem, Inc., the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on October 6, 2017)
